NeoGenomics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell NeoGenomics and other ETFs, options, and stocks.

About NEO

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company was founded by Michael T. 

CEO
Anthony P. Zook
CEOAnthony P. Zook
Employees
2,200
Employees2,200
Headquarters
Fort Myers, Florida
HeadquartersFort Myers, Florida
Founded
1998
Founded1998
Employees
2,200
Employees2,200

NEO Key Statistics

Market cap
1.65B
Market cap1.65B
Price-Earnings ratio
-14.41
Price-Earnings ratio-14.41
Dividend yield
Dividend yield
Average volume
2.43M
Average volume2.43M
High today
$13.00
High today$13.00
Low today
$12.55
Low today$12.55
Open price
$12.83
Open price$12.83
Volume
5.90M
Volume5.90M
52 Week high
$15.32
52 Week high$15.32
52 Week low
$4.72
52 Week low$4.72

Stock Snapshot

The current NeoGenomics(NEO) stock price is $12.75, with a market capitalization of 1.65B. The stock trades at a price-to-earnings (P/E) ratio of -14.41.

During the trading session on 2026-01-17, NeoGenomics(NEO) shares reached a daily high of $13.00 and a low of $12.55. At a current price of $12.75, the stock is +1.6% higher than the low and still -1.9% under the high.

Trading volume for NeoGenomics(NEO) stock has reached 5.9M, versus its average volume of 2.43M.

Over the past 52 weeks, NeoGenomics(NEO) stock has traded between a high of $15.32 and a low of $4.72.

Over the past 52 weeks, NeoGenomics(NEO) stock has traded between a high of $15.32 and a low of $4.72.

NEO News

Simply Wall St 1d
How NeoGenomics’ CFO Transition and Double‑Digit Revenue Guidance Has Changed Its Investment Story

NeoGenomics, Inc. recently announced a planned Chief Financial Officer transition, with industry veteran Abhishek Jain set to assume the CFO role on March 2, 20...

How NeoGenomics’ CFO Transition and Double‑Digit Revenue Guidance Has Changed Its Investment Story
TipRanks 6d
NeoGenomics CFO Jeff Sherman to retire, Abhishek Jain to succeed

NeoGenomics (NEO) also announced a CFO succession plan. Life sciences tools and diagnostics industry veteran Abhishek Jain joined the company as executive VP on...

Analyst ratings

50%

of 14 ratings
Buy
42.9%
Hold
50%
Sell
7.1%

People also own

Based on the portfolios of people who own NEO. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .